Olmesar

Olmesar is a blocking agent for the conductors of the angiotensin II element.

[1], [2]

Indications of the olmesara

It is used with an elevated pressure of the essential type.

[3]

Release form

The release takes place in tablets, 7 pieces inside a blister cell. The box contains 1 or 4 blister packs.

Pharmacodynamics

The substance of medosomil olmesartan is a powerful selective antagonist of the conductors of angiotensin 2 (form АТ1). It slows down the effect of angiotensin 2, which develops with the participation of AT1 conductors, regardless of the binding pathways and the source of angiotensin 2.

Selective antagonism of the above conductors increases the plasma values of renin, and in addition angiotensin 1 and 2. Together with this they slightly reduce the plasma level of aldosterone. With increased blood pressure, the drug contributes to a long-term reduction in pressure (the effect depends on the size of the portion).

There is no information on a strong reduction in blood pressure when taking the first dose, and in addition to the development of tachyphylaxis due to prolonged use of drugs or withdrawal syndrome after discontinuation of admission. The use of a dose of Olmesara once a day leads to a gradual and effective decrease in blood pressure. This effect lasts for 24 hours.

Pharmacokinetics

Olmesar is a pro-drug. The active ingredient quickly converts to a drug-active degradation product of olmesartan. This happens during the absorption of the drug from the digestive tract - under the influence of esterases, which are located inside the portal blood and intestinal mucosa. Inside the plasma or excretion products, there is no undissolved active component or an unchanged side chain of the medocomal category.

The average absolute bioavailability of the substance when taking the pill is 25.6%. In this case, the average maximum level of the active component inside the plasma is observed after 2 hours after use. Plasma values of drugs increase in linear accordance with the increase of a single oral dose of the drug to 80 mg. The use of food has almost no effect on the bioavailability of the drug.

Synthesis of the drug with proteins within the plasma reaches 99.7%, although it should be taken into account that it has a low potential for a noticeable level of protein synthesis in the case of combination therapy with other drugs with high protein binding characteristics. This fact is confirmed by the absence of a medicinal significant interaction of Olmesara with warfarin or medoxomil.

[4]

Dosing and administration

The sizes of portions of a medicine, and also duration of therapy are defined only by the attending physician, separately for each patient.

It is required to take the tablets at the same time, regardless of the use of food - the time of breakfast is suitable for the reception.

The size of the recommended initial portion of Olmesara is 10 mg, which are taken once a day. In the absence of the desired effect, it is possible to increase the dosage to the optimum daily dose, which is 20 mg.

If there is a need for an additional decrease in blood pressure, it is allowed to increase the dosage to the maximum daily dose (it is 40 mg) or to use a combination with hydrochlorothiazide.

The maximum hypotensive effect is observed after 2 months from the start of the course, although a marked decrease in blood pressure is observed after 2 weeks of therapy.

In violation of renal activity.

Persons with moderate functional renal impairment (at a QC level within 20-60 ml / minute) are required to take the drug at a dosage of 20 mg once a day.

People with severe form of renal impairment (at CC values <20 ml / minute) are prohibited from prescribing this medication.

When the hepatic activity is disturbed.

For people with moderate impairment in liver function, the initial dosage is 10 mg once a day, and the maximum allowable dose per day is 20 mg.

[7]

Use of the olmesara during pregnancy

It is forbidden to prescribe the drug to pregnant or lactating mothers.

Contraindications

The main contraindications:

• intolerance of the elements of the drug;
• obstruction affecting the system of VLT;
• the age category is under 18 years of age.

Side effects of the olmesara

Use of the medication can cause some side-effects:

• reactions of CCC organs: occasionally there is an orthostatic type hypotension or a decrease in blood pressure values is observed. Angina is noted singly;
• lesions of the hematopoietic system: thrombocytopenia occurs sporadically;
• violations of the NA: single headaches are noted or dizziness;
• problems in the work of the respiratory system: often there is a pharyngitis, bronchitis or runny nose. There is a cough;
• disorders of the function of the gastrointestinal tract: often there are gastroenteritis, diarrhea or dyspepsia. Occasionally vomiting, abdominal pain or nausea;
• lesions of the subcutaneous layer or skin surface: rashes, itching, allergic dermatitis, puffiness on the face, Quincke edema or urticaria are noted;
• disorders of the musculoskeletal system: often there are pain in the back, arthritis or pain in the skeleton. There is a single myalgia or muscle cramps;
• symptoms affecting the system of urination: often there are infections inside the urinary ducts or hematuria. There is a rare degree of kidney failure;
• systemic lesions: often there are pains in the sternum, flu-like signs and peripheral puffiness. The feeling of general indisposition develops, as well as drowsiness or fatigue;
• indications of laboratory tests: often there is hypertriglyceridemia or hyperuricemia, and also increases the level of CK. Occasionally, hyperkalemia is noted. The indicators of hepatic enzymes, as well as the values of blood urea and creatinine, increase single-digit.

[5], [6]

Overdose

The probability of drug intoxication is low enough. The most likely complication is an excessive decrease in blood pressure.

Treatment procedures are supportive, as well as symptomatic - it is required to increase the level of blood pressure to the required values. There is no information on the excretion of the drug by dialysis.

[8], [9],

Interactions with other drugs

Use in combination with other antihypertensive drugs can potentiate the impact of Olmesar.

As a result of the combination of the drug with NSAIDs, its hypotensive effect may decrease and the risk of developing an acute stage of kidney failure may appear.

In treatment with simultaneous use of antacids (aluminum or magnesium hydroxide), the bioavailability of the drug decreases.

Pharmacokinetic parameters of the drug do not change when combined with digoxin or warfarin.

It is forbidden to combine the drug with lithium drugs, because in this case, the toxic properties of the latter are potentiated.

Because of the high likelihood of hyperkalemia, Olmesar can not be used simultaneously with potassium-sparing diuretics, potassium-containing drugs or other drugs that can increase serum potassium levels (among such drugs heparin).

[10], [11]

Storage conditions

Olmesar is required to be kept in a place that is closed from children's access. Temperature values are not higher than 25 ° C.

Shelf life

Olmesar is allowed to be used for 2 years from the date of manufacture of the medicinal product.